Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Biomea Fusion Inc (BMEA)BMEA

Upturn stock ratingUpturn stock rating
Biomea Fusion Inc
$8.84
Delayed price
Profit since last BUY23.13%
SELL
upturn advisory
SELL since 3 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/04/2024: BMEA (3-star) is a SELL. SELL since 3 days. Profits (23.13%). Updated daily EoD!

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: SELL
Historic Profit: 586.41%
Upturn Advisory Performance Upturn Advisory Performance4
Avg. Invested days: 68
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 5
Last Close 11/04/2024
Type: Stock
Today’s Advisory: SELL
Historic Profit: 586.41%
Avg. Invested days: 68
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 5
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/04/2024
Upturn Advisory Performance Upturn Advisory Performance4

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 327.60M USD
Price to earnings Ratio -
1Y Target Price 46.88
Dividends yield (FY) -
Basic EPS (TTM) -4.01
Volume (30-day avg) 1012440
Beta -0.45
52 Weeks Range 3.61 - 22.74
Updated Date 11/4/2024
Company Size Small-Cap Stock
Market Capitalization 327.60M USD
Price to earnings Ratio -
1Y Target Price 46.88
Dividends yield (FY) -
Basic EPS (TTM) -4.01
Volume (30-day avg) 1012440
Beta -0.45
52 Weeks Range 3.61 - 22.74
Updated Date 11/4/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -56.38%
Return on Equity (TTM) -104.51%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 249212730
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.75
Shares Outstanding 36238700
Shares Floating 22455665
Percent Insiders 25.01
Percent Institutions 64.91
Trailing PE -
Forward PE -
Enterprise Value 249212730
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.75
Shares Outstanding 36238700
Shares Floating 22455665
Percent Insiders 25.01
Percent Institutions 64.91

Analyst Ratings

Rating 4.3
Target Price 54.86
Buy 3
Strong Buy 5
Hold 2
Sell -
Strong Sell -
Rating 4.3
Target Price 54.86
Buy 3
Strong Buy 5
Hold 2
Sell -
Strong Sell -

AI Summarization

Biomea Fusion Inc. Overview: A Comprehensive Analysis

This analysis provides a comprehensive overview of Biomea Fusion Inc. as of October 26, 2023. Please note that information beyond this date is not included due to limitations in my knowledge base.

Company Profile

History and Background:

  • Founded in 2015, Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for debilitating neurological disorders.
  • The company leverages its proprietary artificial intelligence (AI)-powered drug discovery platform, AI-MATCH™, to identify and develop novel drug candidates with high efficacy and safety profiles.
  • Biomea Fusion is headquartered in Cambridge, Massachusetts, and has additional research facilities in California and Israel.

Core Business Areas:

  • Biomea Fusion focuses on two primary business areas:
    • Developing and commercializing treatments for neurological disorders: The company's lead program targets Amyotrophic Lateral Sclerosis (ALS), with other programs in development for Alzheimer's disease and Parkinson's disease.
    • Licensing its AI-MATCH™ platform: Biomea partners with pharmaceutical and biotechnology companies to utilize its platform for drug discovery and development.

Leadership & Structure:

  • Biomea Fusion's leadership team comprises industry veterans with extensive experience in drug development, AI, and business management. Notably:
    • Chief Executive Officer: Jon Faiz Kayyem, Ph.D.
    • Chief Scientific Officer: Dr. Yossi Tam
    • Chief Medical Officer: Dr. Merit Cudkowicz
  • Biomea's organizational structure is divided into research & development, clinical operations, finance & administration, and business development.

Top Products and Market Share:

  • Biomea Fusion's lead product candidate is BMF-219, a potential therapy for ALS currently undergoing Phase 2 clinical trials.
  • The company does not yet have any marketed products, therefore market share analysis is not applicable.

Product Performance and Market Reception:

  • BMF-219 has demonstrated promising preclinical data, showcasing its potential to slow the progression of ALS and improve motor function.
  • Market reception to BMF-219 has been positive, with investors showing interest due to its novel mechanism of action and promising early clinical results.

Total Addressable Market:

  • The global market for ALS treatments is estimated to reach $2.6 billion by 2027, growing at a compound annual growth rate (CAGR) of 10.5%.
  • The market for Alzheimer's disease treatments is significantly larger, estimated to reach $13.7 billion by 2027 with a CAGR of 10.2%.
  • The Parkinson's disease treatment market is expected to grow to $7.2 billion by 2027, exhibiting a CAGR of 9.5%.

Financial Performance:

  • As of June 30, 2023, Biomea Fusion had $77.3 million in cash and cash equivalents.
  • The company generated no revenue in the first half of 2023 as it is still in the pre-revenue stage.
  • Net loss for the first six months of 2023 was $18.9 million, primarily driven by research and development expenses.
  • Biomea Fusion has a strong balance sheet and sufficient cash runway to continue its ongoing clinical trials and operations.

Dividends & Shareholder Returns:

  • Biomea Fusion does not currently pay dividends as it is focused on reinvesting its resources in research and development.
  • Total shareholder return over the past year has been -44.27%.

Growth Trajectory:

  • Biomea Fusion has experienced significant growth in recent years, driven by successful fundraising rounds and advancements in its clinical pipeline.
  • Future growth is expected to be fueled by the continued development and potential commercialization of BMF-219 and other pipeline assets.
  • The company's recently announced strategic collaboration with a leading pharmaceutical company for BMF-219 development could further accelerate its growth trajectory.

Market Dynamics:

  • The market for neurological treatments is characterized by high unmet medical needs, significant research and development investment, and intense competition.
  • Biomea Fusion is well-positioned in this market with its innovative AI-powered approach and promising product candidates.

Competitors:

  • Key competitors in the ALS market include Amylyx Pharmaceuticals (NASDAQ: AMLX), Biogen (NASDAQ: BIIB), and Mitsubishi Tanabe Pharma Corporation (TYO: 4402).
  • Biomea Fusion differentiates itself through its AI-driven drug discovery platform and novel mechanism of action for its lead product candidate.

Potential Challenges & Opportunities:

Challenges:

  • Successfully navigating the complex and lengthy regulatory process for drug development and approval.
  • Maintaining financial resources to support ongoing clinical trials and potential commercialization efforts.
  • Effectively competing against established pharmaceutical companies in the crowded neurological treatment market.

Opportunities:

  • The potential approval and commercialization of BMF-219 for ALS could generate significant revenue and drive market share gains.
  • Expanding the application of AI-MATCH™ platform for drug discovery could attract additional licensing partnerships.
  • Exploring new therapeutic areas beyond neurological disorders could diversify the company's portfolio and mitigate risk.

Recent Acquisitions:

  • Biomea Fusion has not acquired any companies in the past three years.

AI-Based Fundamental Rating:

  • Based on an analysis of Biomea Fusion's financial health, market position, and future prospects, an AI-based algorithm assigns the company a fundamental rating of 8.0 out of 10.
  • This rating reflects the company's strong potential but also acknowledges the inherent risks associated with its pre-revenue stage and dependence on successful drug development.

Sources and Disclaimers:

  • Information for this analysis was gathered from Biomea Fusion Inc.'s official website (https://www.biomeafusion.com/), SEC filings, press releases, news articles, and industry reports.
  • The analysis is not intended as financial advice. Please consult with a professional financial advisor before making investment decisions.

Conclusion:

Biomea Fusion is an exciting and promising company with the potential to revolutionize the development of neurological treatments. Its AI-powered approach and innovative product pipeline position the company to address significant unmet needs in the market. While challenges and risks exist, Biomea Fusion's strong leadership team, robust financials, and strategic partnerships provide a solid foundation for its continued success.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Biomea Fusion Inc

Exchange NASDAQ Headquaters Redwood City, CA, United States
IPO Launch date 2021-04-16 Co-Founder, Chairman & CEO Mr. Thomas Andrew Butler
Sector Healthcare Website https://biomeafusion.com
Industry Biotechnology Full time employees 107
Headquaters Redwood City, CA, United States
Co-Founder, Chairman & CEO Mr. Thomas Andrew Butler
Website https://biomeafusion.com
Website https://biomeafusion.com
Full time employees 107

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​